CN115943160A - 抗oxMIF/抗CD3双特异性抗体构建体 - Google Patents

抗oxMIF/抗CD3双特异性抗体构建体 Download PDF

Info

Publication number
CN115943160A
CN115943160A CN202080093521.XA CN202080093521A CN115943160A CN 115943160 A CN115943160 A CN 115943160A CN 202080093521 A CN202080093521 A CN 202080093521A CN 115943160 A CN115943160 A CN 115943160A
Authority
CN
China
Prior art keywords
ser
gly
thr
val
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093521.XA
Other languages
English (en)
Chinese (zh)
Inventor
A·席纳格尔
R·M·蒂勒
R·克施鲍默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wengke Aonei R & D Co ltd
Original Assignee
Wengke Aonei R & D Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wengke Aonei R & D Co ltd filed Critical Wengke Aonei R & D Co ltd
Publication of CN115943160A publication Critical patent/CN115943160A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080093521.XA 2019-12-06 2020-12-04 抗oxMIF/抗CD3双特异性抗体构建体 Pending CN115943160A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214037 2019-12-06
EP19214037.4 2019-12-06
PCT/EP2020/084676 WO2021110935A1 (en) 2019-12-06 2020-12-04 Anti-oxMIF/anti-CD3 BISPECIFIC ANTIBODY CONSTRUCTS

Publications (1)

Publication Number Publication Date
CN115943160A true CN115943160A (zh) 2023-04-07

Family

ID=68808117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093521.XA Pending CN115943160A (zh) 2019-12-06 2020-12-04 抗oxMIF/抗CD3双特异性抗体构建体

Country Status (8)

Country Link
US (1) US20230045873A1 (https=)
EP (1) EP4069735A1 (https=)
JP (1) JP2023504620A (https=)
KR (1) KR20220110221A (https=)
CN (1) CN115943160A (https=)
AU (1) AU2020397229A1 (https=)
CA (1) CA3161783A1 (https=)
WO (1) WO2021110935A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724430A (zh) * 2008-01-04 2014-04-16 巴克斯特国际公司 抗mif抗体
US20140248638A1 (en) * 2011-10-07 2014-09-04 Baxter Healthcare Sa Oxmif as a diagnostic marker
US20150175699A1 (en) * 2012-06-14 2015-06-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
US20150250873A1 (en) * 2012-04-16 2015-09-10 Baxter Healthcare Sa Combination therapy of anti-mif antibodies and glucocorticoids
CN105722859A (zh) * 2013-07-25 2016-06-29 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN110256567A (zh) * 2012-06-27 2019-09-20 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10259887B2 (en) * 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
US20180155419A1 (en) 2015-05-18 2018-06-07 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras
EP3802595A1 (en) 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
TWI899079B (zh) * 2019-05-23 2025-10-01 美商維洛斯生物公司 抗ror1/抗cd3雙特異性結合分子
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724430A (zh) * 2008-01-04 2014-04-16 巴克斯特国际公司 抗mif抗体
US20140248638A1 (en) * 2011-10-07 2014-09-04 Baxter Healthcare Sa Oxmif as a diagnostic marker
US20150250873A1 (en) * 2012-04-16 2015-09-10 Baxter Healthcare Sa Combination therapy of anti-mif antibodies and glucocorticoids
US20150175699A1 (en) * 2012-06-14 2015-06-25 Therapix Biosciences Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
CN110256567A (zh) * 2012-06-27 2019-09-20 弗·哈夫曼-拉罗切有限公司 用于选择并产生含有至少两种不同结合实体的定制靶向实体的方法及其用途
CN105722859A (zh) * 2013-07-25 2016-06-29 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOUILLARD P., ET AL: "Abstract A153： Imalumab， a first-in-class anti-oxidized macrophage migration inhibitory factor（oxMIF） antibody penetrates tumor tissues and shows antitumor activity in patients", MOL CANCER THER, vol. 14, no. 12, 1 December 2015 (2015-12-01), pages 153 *

Also Published As

Publication number Publication date
JP2023504620A (ja) 2023-02-06
AU2020397229A9 (en) 2023-06-29
WO2021110935A1 (en) 2021-06-10
US20230045873A1 (en) 2023-02-16
KR20220110221A (ko) 2022-08-05
AU2020397229A1 (en) 2022-06-30
CA3161783A1 (en) 2021-06-10
EP4069735A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
JP6392923B2 (ja) Ｍｕｃ１＊抗体
US20220002398A1 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
JP2024156719A (ja) Ｌａｇ３に結合する治療用分子
JP2022551081A (ja) 癌処置のための多重特異性結合タンパク質
CN115943160A (zh) 抗oxMIF/抗CD3双特异性抗体构建体
JP2020522267A (ja) 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット
US20250051467A1 (en) Fap/cd40 binding molecule and medicinal use thereof
JP7851303B2 (ja) ヒトｃｄ３イプシロンに結合する新規なヒト抗体
CN113490690A (zh) 异源二聚体融合蛋白
CN119173528A (zh) 针对cd277和肿瘤抗原的双特异性抗体
JP2026507108A (ja) Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及びその医薬的使用
JP2023547662A (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
CN116437949A (zh) 剪切速率降低的抗原结合结构域
KR20230104229A (ko) Cd3에 결합하는 폴리펩티드 구축물
JP2023545968A (ja) 低減された凝集能及び低減された疎水性を有する改善された抗ｏｘＭＩＦ抗体
HK40073540B (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
WO2025082777A1 (en) Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
EP4702049A1 (en) Novel egfr binding proteins
HK40129137A (zh) 制导和导航控制(gnc)抗体样蛋白及其制备和使用方法
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230407